Back to results
US 9,872,855 B2Granted
(2R,4R)-5-(5′-Chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
AssigneeTheravance Biopharma R&D IP, LLC
InventorsMelissa Fleury, Adam D. Hughes, Anne-Marie Beausoleil, Erik Fenster, Venkat R. Thalladi, Miroslav Rapta
Life of this patent
Estimating the term…
Abstract
In one aspect, the invention relates to a compound of the structure: or a pharmaceutically acceptable salt thereof, and a crystalline form of this compound, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising this compound; methods of using this compound; and processes for preparing this compound.
Claims9
A pharmaceutical composition comprising a compound of the following structure:
- or a pharmaceutically acceptable salt thereof, and an AT1 receptor antagonist or a pharmaceutically acceptable salt thereof;
- wherein the AT1 receptor antagonist is selected from the group consisting of abitesartan, azilsartan, azilsartan medoxomil, benzyllosartan, candesartan, candesartan cilexetil, elisartan, embusartan, enoltasosartan, eprosartan, EXP3174, fonsartan, forasartan, glycyllosartan, irbesartan, isoteoline, losartan, medoxomil, milfasartan, olmesartan, olmesartan medoxomil, opomisartan, pratosartan, ripisartan, saprisartan, saralasin, sarmesin, TAK-591, tasosartan, telmisartan, valsartan, and zolasartan;
- and
- wherein the compound is optionally in a crystalline form.
1 more element
Dependencies are inferred from the claim text.